We therefore studied one year mortality among patients with and without DM in a large cohort of patients with acute STEMI treated with primary PCI. Furthermore, we studied the impact of preadmission treatment for DM, either oral medication or with insulin.
METHODS
Between January 1997 and December 2002, 1463 consecutive and unselected patients were admitted to our hospital with acute STEMI. Of the 1463 patients, 17 were lost to follow up and for another 138 patients data about DM status was not available. The remaining 1308 patients constituted the study cohort. Follow up information was obtained one year after the initial event by written questionnaire sent to all patients. If necessary outpatients' reports were reviewed and general practitioners were contacted by telephone. Baseline clinical and angiographic data were collected prospectively on a dedicated database. The patients were categorised as being without DM or as having an established diagnosis of DM at admission. Patients with DM were categorised according to preadmission treatment: either with oral medication or diet controlled DM (non-insulin dependent DM (NIDDM)) or with insulin (insulin dependent DM (IDDM)). IDDM comprised both type 1 and type 2 DM. Patients treated with insulin in combination with oral medication were categorised as having IDDM.
To find independent predictors of one year mortality we performed multivariate analysis with a Cox proportional hazards regression model. 
RESULTS

Of
DISCUSSION
This study confirms that even with the reperfusion treatment of choice, patients with STEMI and DM have a greater long term mortality than do patients without DM. They have different baseline characteristics from patients without DM. Patients with DM also present with a higher incidence of cardiogenic shock, possibly at least partly due to a longer ischaemic time. Furthermore, more patients with than without DM had PCI failure possibly also as a consequence of a longer ischaemic time. Some angiographic differences may also partly explain the difference in PCI success. Both coronary calcifications and a higher rate of multivessel disease are also associated with more complicated PCI procedures and were more common among patients with DM.
The second finding is that preadmission treatment for DM is an independent predictor for one year mortality. Patients requiring insulin have longstanding type 1 DM or type 2 DM without adequate glycaemic regulation with oral medication. These patients with IDDM mostly have longstanding DM and mortality of those with type 2 DM receiving insulin at admission is about four times higher than that of patients without DM and two times higher than that of patients with DM taking oral medication at admission. In our study about 13% of the patients had a previous diagnosis of DM. Of all the Abbreviations: DM, diabetes mellitus; IDDM, insulin dependent diabetes mellitus; NIDDM, non-insulin dependent diabetes mellitus; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction patients with DM about 28% were taking insulin at admission, in agreement with large registries.
As a limitation, we did not routinely estimate haemoglobin A 1c or test for DM on admission or during follow up. Despite the relatively large sample size, the absolute number of patients in each DM category is somewhat small. Only 23% of all patients were treated with abciximab.
Patients with acute STEMI with diagnosed DM more often present with cardiogenic shock and have more severe coronary disease and PCI failure. After primary PCI for STEMI, the one year mortality rate is 7.2% for patients without DM and 17.8% for patients with DM. For patients with DM taking oral medication at the time of admission for STEMI, the one year mortality is 14.3% and for those taking insulin mortality is 27.1%. Preadmission treatment for DM is an independent predictor of one year mortality. Even after primary PCI for acute STEMI, patients with DM treated with insulin form a subgroup with a mortality about four times higher than that of patients without DM and two times higher than that of patients with DM treated with oral medication in daily, real life clinical practice. Myocardial ischaemia in a patient with anomalous left coronary artery from the pulmonary artery A 52 year old man presented with near syncope while standing in a bus. An ECG showed widespread T wave inversion involving lead V1-4, I, aVL. Myocardial infarction was ruled out on subsequent cardiac enzyme assays. A dobutamine stress echocardiogram showed abnormal wall motion in the left anterior descending artery territory during stress. Cardiac catheterisation showed a large right coronary artery collateralising the left coronary artery, which emptied into the pulmonary artery (panel). There was no significant coronary artery disease and the left ventricular systolic function was normal. The calculated left to right shunt (Qp:Qs ratio) was 1.07.
Anomalous left coronary artery from the pulmonary artery is a rare, congenital cardiac anomaly accounting for approximately 0.25-0.5% of all congenital heart disease. It is usually an isolated cardiac anomaly but, in rare incidences, has been described with patent ductus arteriosus, ventricular septal defect, tetralogy of Fallot, and coarctation of the aorta. Collateral circulation between the right and left coronary systems ensues after birth and the left ventricular myocardium is chronically underperfused, since flow is preferentially directed into the pulmonary vascular bed and away from the left ventricular myocardium due to the low pulmonary vascular resistance (coronary steal phenomena). Left untreated, the mortality rate in the first year of life is 90% secondary to myocardial ischaemia or infarction and congestive heart failure. In rare cases, the clinical presentation of myocardial ischaemia may be delayed into early childhood, or even adulthood as in our patient, when intracardiac shunt is minimal.
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